NDANASALSPRAY
Approved
Sep 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
ZOMIG (zolmitriptan) by Ichnos Glenmark Innovation is serotonin 1b receptor agonists [moa]. Approved for migraine. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMIG (zolmitriptan) is a serotonin 5-HT1B/1D receptor agonist (triptan) administered as a nasal spray for acute migraine treatment. It works by constricting cranial blood vessels and reducing substances in the body that cause headache, pain, sensitivity to light, and other migraine symptoms. The product targets patients experiencing active migraine episodes seeking rapid symptom relief.
LOE Approaching
Product is in late-stage patent lifecycle with moderate competitive pressure (30/100), indicating consolidating market share and team focus shifting toward lifecycle extension or transition planning.
Mechanism of Action
Serotonin 1b Receptor Agonists
Pharmacologic Class:
Serotonin-1b and Serotonin-1d Receptor Agonist
Indications (1)
Clinical Trials (5)
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
Started Nov 2017
374 enrolled
Migraine
Zomig - Treatment of Acute Migraine Headache in Adolescents
Started Sep 2010
1,653 enrolled
Migraine Headache
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Started May 2010
10 enrolled
Migraine
ZAP, US. Zomig for Appropriate for Primary Care
Started Jul 2004
120 enrolled
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
Started Sep 2002
2,114 enrolled
Migraine
Worked on ZOMIG at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.